Company Encyclopedia
View More
name
Biovie
BIVI.US
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc.
1.946 T
BIVI.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Biotech Stocks Swing After Hours: Delcath Rises On Buyback, BioVie And Cassava Rebound

    After-hours trading saw biotech stocks like Delcath Systems rise due to a $25 million buyback announcement, reflecting confidence in its long-term outlook. BioVie, Cassava Sciences, and Enlivex Therapeutics also rebounded despite no new headlines. Cassava's rise follows its Q3 results showing a reduced net loss and strong cash position.

    rttnews·
    US
    DCTH
    +3.73%
    US
    SAVA
    +7.10%
    US
    ENLV
    +6.42%
    rttnews·
    US
    DCTH
    +3.73%
    US
    SAVA
    +7.10%
    US
    ENLV
    +6.42%

    BioVie Stockholders Approve Key Proposals at Annual Meeting

    BioVie Inc. held its annual stockholders' meeting on November 10, 2025, where key proposals were approved, including the election of directors, the appointment of EisnerAmper LLP as auditors, and an amendment to increase shares in the 2019 Omnibus Equity Incentive Plan. Analysts rate BIVI stock as a Buy with a $12.00 target, but Spark's AI Analyst indicates an Underperform rating due to financial challenges, high cash burn, and bearish technical indicators. BioVie currently has a market cap of $11.75M and an average trading volume of 216,774.

    Tip Ranks·
    US
    BIVI
    +1.26%
    Tip Ranks·
    US
    BIVI
    +1.26%

    Biovie | 10-Q: FY2026 Q1 Revenue: USD 0

    LB filings·
    US
    BIVI
    +1.26%
    LB filings·
    US
    BIVI
    +1.26%

    BIOVIE INC. SEC 10-Q Report

    BioVie Inc. has released its Form 10-Q report for Q3 2025, reporting a net loss of $5.1 million, an increase from the previous year. The company is advancing its neurodegenerative disease program with bezisterim, conducting clinical trials for Alzheimer's, Parkinson's, and long COVID. A Phase 2b study for Parkinson's has begun, and a $13.1 million grant has been received for long COVID research. The Phase 3 trial for Alzheimer's faced challenges but showed potential benefits. BioVie is also developing BIV201 for liver disease and is seeking additional financing for its programs.

    TradingView·
    US
    BIVI
    +1.26%
    TradingView·
    US
    BIVI
    +1.26%

    BioVie Inc. Files Initial Beneficial Ownership Statement for Director Amy Suzon Chappell

    BioVie Inc. has filed an initial beneficial ownership statement with the U.S. SEC, listing Amy Suzon Chappell as the beneficial owner in her role as a director. The full filing is accessible via the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    BIVI
    +1.26%
    Reuters·
    US
    BIVI
    +1.26%
    © 2025 Longbridge｜Disclaimer